(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/204219 A1

(51) International Patent Classification:
A61K 9/12 (2006.01) *A61K 47/28* (2006.01)
A61K 9/00 (2006.01) *A61K 48/00* (2006.01)
A61K 47/24 (2006.01) *A61K 9/51* (2006.01)

(21) International Application Number:
PCT/US2022/021442

(22) International Filing Date:
22 March 2022 (22.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/164,523	22 March 2021 (22.03.2021)	US
63/229,497	04 August 2021 (04.08.2021)	US
63/305,426	01 February 2022 (01.02.2022)	US

(71) Applicants: **RECODE THERAPEUTICS, INC.** [US/US]; 1455 Adams Drive, Menlo Park, California 94025 (US). **THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, Texas 78701 (US).


(72) Inventors: **HENNIG, Mirko**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **KHARITONOV, Vladimir**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **WUSTMAN, Brandon**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **EBY, Jackson**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **BHATTACHARJEE, Rumpa**; c/o ReCode Therapeutics, Inc., 1455 Adams Drive, Menlo Park, California 94025 (US). **SIEGWART, Daniel**; c/o The Board of Regents of the University of Texas System, 210 West 7th Street, Austin, Texas 78701 (US).

(74) Agent: **LIN, Yinan**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

WO 2022/204219 A1

(54) Title: COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS

Fig. 16A



(57) **Abstract:** Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*